SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 9, 2026

GILD

GILEAD SCIENCES, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 2h ago
Insider cluster: 2 insiders, $2.3M total
Actionable Insight • Neutral

The sales are pre-planned and de minimis relative to market cap. No bearish signal; the strong Q3 beat and raised revenue guidance are the dominant factors. Monitor for any unplanned insider sales in the coming weeks.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$170.87
T+0 close · Nov 9, 2026 · via day close
Latest settled
−0.67%
T+1 · $169.73
Vs SPY
−1.99%
α at T+1
Next horizon
T+5
in 9h
  1. T+0 · Nov 10 $170.87entry
  2. T+1 · 6d ago −0.67%α −1.99% · $169.73
  3. T+4 · todayOpen
  4. T+5 · in 9h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two Gilead insiders (CEO and EVP/General Counsel) sold a combined $2.28M in open-market sales under 10b5-1 plans within a week of the company's strong Q3 2026 earnings beat. The CEO's sales total $1.72M and the GC's $558K; both are pre-planned and represent a negligible fraction of Gilead's $207.8B market cap.

Key Financial Metrics

Direction
selling
Total Value
$2.3M
Insiders
2

Key Facts

  • CEO O'Day sold 9,810 shares at $175.17 ($1.72M) on 2026-11-05 under a 10b5-1 plan
  • EVP/GC Cain Wettan Keeley sold 3,399 shares at $164.11 ($558K) on 2026-11-06 under a 10b5-1 plan
  • Total open-market sales: $2.28M, which is ~0.001% of Gilead's $207.8B market cap
  • Sales occurred 7-8 days after Gilead reported Q3 2026 product sales of $8.3B (+13% YoY) and non-GAAP EPS of $2.55, beating consensus of $2.19
  • Both sales are under 10b5-1 plans, indicating pre-arranged trading programs

Financial Impact

Total insider sales of $2.28M, immaterial relative to $207.8B market cap (0.001%)

Risk Factors

  • Insider sales are routine and pre-planned; no elevated risk
  • No material risk identified from this cluster

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-GILD-1794270061949

Track record

30 reports on GILD

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
  2. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
  3. Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Viewing Entry $170.87 Now $167.58 −1.93% settles Feb 8
  6. Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
  7. Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
  8. Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
  9. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
  10. Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
Showing 10 of 30

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026